Chetan Lathia
- Hepatology top 0.5%
- Hepatocellular Carcinoma Treatment and Prognosis 7
- Cancer Research top 1%
- Oncology top 2%
- Colorectal Cancer Treatments and Studies 10
- Cancer Treatment and Pharmacology 8
-
- Lung Cancer Treatments and Mutations 9
-
- Melanoma and MAPK Pathways 9
- PI3K/AKT/mTOR signaling in cancer 7
- Cancer therapeutics and mechanisms 6
-
- Pharmacogenetics and Drug Metabolism 5
- Co-authors
- Brian SchwartzCarol E. PeñaArmando SantoroM. MoscoviciJacques De GrèveArié FigerSergio RicciDino Amadori
- Cited by
- HepatologyCancer ResearchOncology
- Journals
- Journal of Clinical Oncology (13 papers)Clinical Cancer Research (8 papers)Arteriosclerosis Thrombosis and Vascular Biology (1 paper)
- Partner nations
- United StatesGermanyCanada
In The Last Decade
Chetan Lathia
51 papers receiving 4.3k citations
Hit Papers
Peers
Comparison fields: 5 of 103
- Hepatology 1.3k
- Cancer Research 1.2k
- Oncology 1.6k
- Pulmonary and Respiratory Medicine 1.5k
- Pathology and Forensic Medicine 709
Countries citing papers authored by Chetan Lathia
This map shows the geographic impact of Chetan Lathia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chetan Lathia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chetan Lathia more than expected).
Fields of papers citing papers by Chetan Lathia
This network shows the impact of papers produced by Chetan Lathia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chetan Lathia. The network helps show where Chetan Lathia may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Chetan Lathia, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2012 | 20 | |
| 2 | 2011 | 18 | |
| 3 | 2011 | 43 | |
| 4 | 2010 | 16 | |
| 5 | Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trialbreakdown → | 2009 | 864 |
| 6 | 2008 | 28 | |
| 7 | 2008 | 45 | |
| 8 | 2005 | 256 | |
| 9 | 2005 | 25 | |
| 10 | 2005 | 4 | |
| 11 | 2005 | 5 | |
| 12 | 2004 | 6 | |
| 13 | 2004 | 6 | |
| 14 | 2003 | 46 | |
| 15 | 2002 | 9 | |
| 16 | 2001 | 1 | |
| 17 | 2000 | 102 | |
| 18 | 1997 | 0 | |
| 19 | 1997 | 1 | |
| 20 | 1997 | 9 |
About Chetan Lathia
Chetan Lathia is a scholar working on Oncology, Hepatology and Cancer Research, having authored 53 papers that have together received 4.4k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (10 papers), Melanoma and MAPK Pathways (9 papers), Lung Cancer Treatments and Mutations (9 papers), Cancer Treatment and Pharmacology (8 papers), PI3K/AKT/mTOR signaling in cancer (7 papers), Hepatocellular Carcinoma Treatment and Prognosis (7 papers), Cancer therapeutics and mechanisms (6 papers) and Pharmacogenetics and Drug Metabolism (5 papers). The work is most often cited by research in Hepatology (1.3k citations), Cancer Research (1.2k citations) and Oncology (1.6k citations). Chetan Lathia has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Brian Schwartz, Carol E. Peña, Armando Santoro, M. Moscovici, Jacques De Grève, Arié Figer, Sergio Ricci, Dino Amadori, Ghassan K. Abou‐Alfa and Jordi Bruix. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research and Arteriosclerosis Thrombosis and Vascular Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.